Regeneron Pharmaceuticals REGN
$
Relative Strength Index (RSI)
- The Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. It is typically used to identify overbought or oversold conditions in financial markets.
- The RSI is calculated using the following formula:
RSI = 100 - (100 / (1 + RS))
Where RS is the ratio of the average gains to the average losses over a specified period.
- The default time period used is 14 days.
- RSI values range between 0 and 100.
RSI values above 70 are considered overbought (indicating a potentially opportune time to sell)
RSI values below 30 are considered oversold (indicating a potentially opportune time to buy)
RSI is not a perfect indicator and should be used in conjunction with other technical analysis tools, this is for informational purposes only and is not a substitute for professional financial advice.
About
Regeneron Pharmaceuticals (REGN) Business Model and Operations Summary
Regeneron Pharmaceuticals Inc discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including low-dose Eylea and Eylea HD, approved for wet age-related macular degeneration and other eye diseases; Dupixent in immunology; Praluent for LDL cholesterol lowering; Libtayo in oncology; and Kevzara in rheumatoid arthritis. Regeneron is also developing monoclonal and bispecific antibodies with Sanofi, other collaborators, and independently, and has earlier-stage partnerships that bring new technology to the pipeline, including RNAi (Alnylam) and Crispr-based gene editing (Intellia).
Key Insights
Regeneron Pharmaceuticals (REGN) Core Market Data and Business Metrics
Latest Closing Price
$617Market Cap
$67.56 BillionPrice-Earnings Ratio
16.09Total Outstanding Shares
107.51 Million SharesTotal Employees
15,106Dividend
No dividendIPO Date
April 2, 1991SIC Description
Pharmaceutical PreparationsPrimary Exchange
NASDAQHeadquarters
777 Old Saw Mill River Road, Tarrytown, NY, 10591
Historical Stock Splits
| Execution Date | Split Amount |
|---|---|
| No Historical Stock Splits | |
Cash Flow Statement
January 1, 2024 to December 31, 2024
| Metric | Value |
|---|---|
| Net Cash Flow | $-248.80 Million |
| Net Cash Flow From Investing Activities, Continuing | $-2.47 Billion |
| Net Cash Flow From Financing Activities | $-2.20 Billion |
| Net Cash Flow From Operating Activities, Continuing | $4.42 Billion |
| Net Cash Flow, Continuing | $-248.10 Million |
| Net Cash Flow From Investing Activities | $-2.47 Billion |
Income Statement
January 1, 2024 to December 31, 2024
| Metric | Value |
|---|---|
| Net Income/Loss | $4.41 Billion |
| Operating Income/Loss | $3.99 Billion |
| Net Income/Loss Attributable To Noncontrolling Interest | $0 |
| Income/Loss From Continuing Operations After Tax | $4.41 Billion |
| Participating Securities, Distributed And Undistributed Earnings/Loss, Basic | $0 |
| Benefits Costs and Expenses | $9.42 Billion |
Comprehensive Income
January 1, 2024 to December 31, 2024
| Metric | Value |
|---|---|
| Other Comprehensive Income/Loss | $4.49 Billion |
| Comprehensive Income/Loss Attributable To Noncontrolling Interest | $0 |
| Other Comprehensive Income/Loss Attributable To Parent | $73 Million |
| Comprehensive Income/Loss | $4.49 Billion |
| Comprehensive Income/Loss Attributable To Parent | $4.49 Billion |
Balance Sheet
January 1, 2024 to December 31, 2024
| Metric | Value |
|---|---|
| Liabilities And Equity | $37.76 Billion |
| Intangible Assets | $1.15 Billion |
| Assets | $37.76 Billion |
| Inventory | $3.09 Billion |
| Noncurrent Liabilities | $4.46 Billion |
| Current Liabilities | $3.94 Billion |
Historical Dividends
| Announcement Date | Payment Date | Record Date | Amount | Frequency |
|---|---|---|---|---|
| No historical dividends | ||||